ClinicalTrials.gg
RecruitingNCT05410730Updated Jan 28, 2025

A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

A Phase 1/2 interventional study of SHR-1501 in High-risk NMIBC, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China — 40 open to participants now, 44 under way, 10 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · China.

Planned enrollment
20th of 47
150 · median 114
Started
2022
with 3 others
Phase 1/2
8 of 50
7 open now
Primary completion
2025-05
later than 4 of 43 live
Registered
8th of 50
by date
Lead sponsor
2 of 50
Shanghai Hengrui Pharmaceutical Co., Ltd.

Among the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, this one is the 20th largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2022, is one of 8 in phase 1/2, reaches primary completion later than 4 of the 43 other live ones, and was the 8th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

40 of the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in combination with BCG or SHR-1316.

To evaluate the preliminary efficacy of SHR-1501 alone or in combination with BCG or SHR-1316 in the treatment of NMIBC.

03

Conditions studied

  • High-risk NMIBC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this clinical study, understand the research procedures and be able to sign the in writing;
  2. Age ≥ 18 years old, gender is not limited;
  3. (ECOG) performance status score ≤2;
  4. Expected survival time ≥ 2 years;
  5. High-risk NMIBC diagnosed by previous pathological
  6. Cystoscopy within 6 weeks before the first administration shows that the lesion has been completely removed, or the residual lesion is only carcinoma in situ; for T1 stage lesions, postoperative pathological results must show the presence of bladder muscle tissue;
  7. ineligible or unwilling to undergo radical cystectomy;
  8. The level of organ function is good.
  9. use measures (such as intrauterine device and contraceptive pill) during the study treatment period and within 3 months after the end of the study treatment period, and the female subject and the female partner of the male subject should use highly effective contraceptive methods; the female subject of childbearing age without surgical sterilization must be negative for serum HCG within 7 days before the first administration and must be non-lactating.

Exclusion criteria

Exclusion Criteria:

  1. Received surgery or radiotherapy for bladder lesions within 2 weeks before the first administration;
  2. Those who have previously received the following treatments and have not experienced disease progression before enrolment t as assessed by the investigator:

    • Intravesical instillation of cytotoxic chemotherapy or other drugs;
    • ;
    • Other products for the treatment of NMIBC.
  3. Currently receiving study treatment in other clinical trials or less than 4 weeks from last participation to the first administration of this study;
  4. Upper urinary tract tumor detected by CTU or MRU during screening period, urethral prostate tumor detected by cystoscopy, or other concomitant malignant tumors within 5 years before the first administration;
  5. Previous medical history or examination suggests active tuberculosis within 1 year prior to the first dose;
  6. Serious infection within 4 weeks before the first administration, or undefined fever>38.5 ℃ during screening/before the first administration;
  7. Obvious urinary tract infections and gross hematuria, indicating safety issues assessed by the investigators;
  8. Patients who discontinued treatment due to adverse reactions such as toxemia, systemic infection or urinary incontinence during previous BCG treatment;
  9. Using of drugs within 2 weeks prior to the first administration, excluding nasal and inhaled , low physiological doses of systemic steroids, and prophylactic anti allergic steroids;
  10. Active or history of interstitial lung disease;
  11. History of cardiovascular disease
  12. A history of immunodeficiency, including seropositive, other acquired or congenital immunodeficiency diseases, a history of organ transplantation, or those who are using immunosuppressants;
  13. With a history of active disease;
  14. Patient with active (HBeAg positive and HBV DNA ≥ 500 IU/mL), (HCV antibody positive and HCV RNA higher than the detection limit of the analytical method);
  15. Known allergic or intolerance to study drug, BCG (Phase Ib and Phase II subjects only) or ;
  16. The presence of other serious physical or mental illness, abnormal laboratory tests, and other factors that may increase the risk of participating in the study, or interfere with the results of the study; and any other conditions that the investigator deems inappropriate to participate in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    SHR-1501

    * Phase I:Phase Ia and Ib: Phase Ia include SHR-1501 dose escalation and expansion; Phase Ib : SHR-1501 in combination with BCG or SHR-1316 dose escalation * Phase II:SHR-1501 in combination with BCG or SHR-1316 dose expansion in NMIBC

    Drug: SHR-1501

Interventions

  • SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity

    Time frame: 21 Days

  2. Maximum tolerated dose

    Time frame: Approximately 2years

  3. Recommended Phase 2 dose (RP2D)

    Time frame: Approximately 2 years.

  4. CR Rate (cohort 2)

    Time frame: Approximately 4 years.

  5. 12-month DFS Rate (cohort 1、3、4)

    Time frame: Approximately 4 years

Secondary outcomes

  1. Treatment-Related Adverse Events as assessed by CTCAE v5.0

    Time frame: Approximately 4 years.

  2. Duration of CR (DoR)

    Time frame: Approximately 4 years.

  3. CR rate at 6 months and 18 months

    Time frame: Approximately 4 years.

  4. DFS

    Time frame: Approximately 4 years.

  5. Time to cystectomy,

    Time frame: Approximately 4 years.

  6. Radical cystectomy rate;

    Time frame: Approximately 4 years.

  7. The amount of drug recovered in perfusate and urine after SHR-1501 perfusion

    Time frame: Approximately 5 years.

  8. Maximum concentration (Cmax) of SHR-1501

    Time frame: Approximately 2 years, if applicable

  9. Time to maximum concentration (Tmax) of SHR-1501

    Time frame: Approximately 2 years,if applicable

  10. Areas under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of SHR-1501

    Time frame: Approximately 2 years,if applicable

  11. Areas under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of SHR-1501

    Time frame: Approximately 2 years,if applicable

  12. Half-life (t1/2) of SHR-1501

    Time frame: Approximately 2 years, if applicable

  13. Apparent clearance (CL/F) of SHR-1501

    Time frame: Approximately 2 years, if applicable

  14. Apparent volume of distribution (V/F) of SHR-1501

    Time frame: Approximately 2 years, if applicable

  15. Concentration of SHR-1501 in Urine

    Time frame: Approximately 2 years, if applicable

  16. Anti-drug antibody of SHR-1501

    Time frame: Approximately 2 years

  17. Neutralizing antibody of SHR-1501

    Time frame: Approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for May 2025, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
Jun 8, 2022
StartActual
Nov 23, 2022
Primary completionEst.
May 2025
CompletionEst.
May 2027
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05410730
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Nov 23, 2022
Primary completion
May 2025 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 28, 2025

Study contacts

Wenliang Wang
Contact
Wenliang.wang@hengrui.com
+0518-81220121
Zhijun Yu
Contact
zhijun.yu.zy19@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efserakefusp alfa

Start the discussion